Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Unlock Full ALNY Analysis
UpgradeKey Numbers
Market Cap
$30B
P/E
N/A
Revenue Growth
+40.0%
Gross Margin
N/A
ROE
N/A
About Alnylam Pharmaceuticals
As a mid-cap biotech company trading on the NASDAQ, Alnylam Pharmaceuticals has established itself, with direct, concentrated exposure to the biotech and genomics theme. RNA interference therapeutics leader with approved treatments for rare diseases. With a $30B market capitalization and no current profitability, the company demonstrates exceptional revenue growth at +40% year-over-year.
Expert Coverage
Loading coverage...
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-03-21
More in Biotech & Genomics
ARKG
ARK Genomic Revolution ETF
89
True North
Mixed
ETF focused on companies advancing genomics, gene editing, and therapeutics.
CBOE
MCap $2BDXCM
DexCom Inc.
85
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55LLY
Eli Lilly and Company
85
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65BEAM
Beam Therapeutics
84
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3B